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Abstract 
Background 
Pregnancy is a hypercoagulable state associated with an increased risk of venous thrombosis, 
which begins during the first trimester, but the exact time of onset is unknown. Thrombin 
generation, a laboratory marker of thrombosis risk, increases during normal pregnancy but it 
is unclear exactly how early this increase occurs. 
 
Methods 
We assessed thrombin generation by Calibrated Automated Thrombography in women 
undergoing natural cycle in vitro fertilization, who subsequently gave birth at term following 
a normal pregnancy (n=22). Blood samples were taken just prior to conception and repeated 
five times during very early pregnancy, up to Day 59 estimated gestation. 
 
Results 
Mean Endogenous Thrombin Potential (ETP), peak thrombin generation and Velocity Index 
(VI) increased significantly from pre-pregnancy to Day 43 gestation (P = 0.024 - 0.0004). 
This change persisted to Day 59 gestation. The mean of the percentage change from baseline, 
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accounting for inter-individual variation, in ETP, peak thrombin and VI increased 
significantly from pre-pregnancy to Day 32 gestation (P = 0.0351 - <0.0001) with the mean 
increase from baseline persisting to Day 59 gestation.  
 
Conclusion 
Thrombin generation increases significantly during the very early stages of normal pregnancy 
when compared to the pre-pregnancy state. The increased risk of venous thrombosis therefore 
likely begins very early in a woman’s pregnancy, suggesting that women considered 
clinically to be at high thrombotic risk should start thromboprophylaxis as early as possible 
after a positive pregnancy test.  
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Introduction 
Pregnancy is a prothrombotic state, likely arising from a physiological response to reduce the 
risk of bleeding during the antenatal, and particularly the postnatal, period. As a result, 
pregnant women are at increased risk of venous thrombosis compared to the general 
population. Epidemiological data suggests that hypercoagulability begins early in pregnancy, 
with an increase in thrombotic risk beginning in the first trimester [1-3]. However, it is 
unknown exactly how early in pregnancy that the hypercoagulable state begins to develop.  
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Thrombin generation, a global coagulation assay, has been demonstrated to more accurately 
reflect the thrombotic phenotype than measuring individual parameters of the coagulation 
cascade [4-8]. Thrombin is pivotal to the coagulation cascade; it is the enzyme responsible 
for converting fibrinogen to fibrin, the step resulting in clot formation. Thrombin also has 
numerous positive and negative feedback roles across the coagulation cascade, thus making it 
central to this process. It is therefore reasonable to expect that an assessment of an 
individual’s ability to generate thrombin will provide an accurate evaluation of an 
individual’s potential to clot. 
  
Studies assessing thrombin generation during pregnancy have been undertaken but have had 
various limitations in their findings [7, 9-14]. Rarely has thrombin generation been assessed 
earlier than 10 weeks of gestation, the late stage of the first trimester, and most studies have 
not obtained pre-pregnancy samples from the same women, preventing an account to be taken 
of the known significant inter-individual variability in thrombin generation [15-16]. 
Frequently the demonstration that pregnancy is associated with an increase in thrombin 
generation has been through comparisons of thrombin generation results obtained from either 
normal pooled plasma or from using postpartum samples from the previously pregnant 
women [9, 11-14]. Other potential confounders such as the use of low molecular weight 
heparin (LMWH) have also affected data [12-13]. 
 
In only one study have the same women been recruited pre-pregnancy and then followed up 
with samples taken during pregnancy [10]. In this study, thrombin generation was 
significantly increased in 20 healthy pregnant women at 11-15 weeks of gestation when 
compared to measurements taken in the same women prior to pregnancy. However, to date, 
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no similar comparisons have been made at an earlier gestation. Furthermore, although this 
study compared mean thrombin generation values between pre-pregnancy and pregnancy, it 
did not report the mean change in thrombin generation per individual over this time period, 
and therefore the significant inter-individual variability known to occur in thrombin 
generation was not accounted for. 
 
Our study is a prospective analysis of thrombin generation in women undergoing natural 
cycle in vitro fertilization, as such women provide the most practical method of obtaining, to 
an extent, accurately timed peri–conceptual and early pregnancy samples and are the best 
physiological representation of a ‘normal’ pregnancy, outside a free living population. These 
women subsequently gave birth at term following a normal pregnancy.  
 
Our aim was to explore the time of onset of increased thrombin generation in pregnancy, as 
an indication of the development of the prothrombotic state, and in turn, guide clinicians as to 
how early preventative measures should be taken in pregnant women at high risk of 
thrombosis.  
 
 
 
Materials and Methods 
CAT Reagents 
PPPLow reagent (1 pM tissue factor [TF] and 4 mM phospholipids [PL]), PPP reagent (5 pM 
TF and 4 mM PL), Thrombin Calibrator (TCal), FluCa (2.5 mM fluorogenic synthetic 
substrate, 100 mM calcium chloride) and Immulon round bottom 96 well microtitre plates 
were purchased from Diagnostica Stago (Asnières, France). Normal Pooled Plasma (NPP) 
and Thrombomodulin (TM) were donated by Cardiovascular Research Institute Maastricht 
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(CARIM), The Netherlands. TGT Reference plasma (TGT-RP) was a gift from NIBSC 
(Potters Bar, Hertfordshire, UK).  
 
Subjects  
Women undergoing natural cycle in vitro fertilization i.e. no hormonal treatment during the 
cycle, were recruited consecutively from the Assisted Conception Service at Glasgow Royal 
Infirmary between October 2007 and June 2010. Demographic data was collected and blood 
samples taken pre-pregnancy and during the very early stages of pregnancy as described 
below. Women were subsequently followed up throughout pregnancy and to delivery, 
including the outcome of their baby. Only those women who developed no complications and 
received no concomitant therapy throughout pregnancy and delivered a normal baby at term 
were included in the final analysis. 
 
The study had full ethical and R&D approval from Glasgow Royal Infirmary Research and 
Ethics Committee (Ref. No. 07/S0704/49) and Research and Development Office (Ref. No. 
RN07OB005). Written informed consent was obtained for every participant. 
 
Blood Samples 
Blood samples were collected in sodium citrate, centrifuged at 3000 rpm for 15 minutes at 
4ºC within 2 hours of plasma collection. Plasma was then spun in a microfuge at 13,000 rpm 
for 4 minutes to obtain platelet poor plasma (PPP) and stored at -80ºC.  Two pre-pregnancy 
samples were taken from each woman; approximately at the time of the lutenizing hormone 
surge (Study Day 0) and at the time of frozen embryo transfer (Study Day 3). Within the 
study, Study Day 0 was considered to be equivalent to Day 14 from last menstrual period 
(LMP) (assuming a 28 day menstrual cycle) in a naturally occurring pregnancy i.e. 2 weeks 
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gestation. Up to a further 5 samples were then taken from the same women very early in 
gestation, at Study Day 7, 10, 18, 29 and 45, with Study Day 45 being equivalent to Day 59 
estimated gestation (Figure 1).  
 
 
Calibrated Automated Thrombography (CAT) 
Thrombin generation (TG) was measured according to the method previously described by 
Hemker in a Fluoroskan Ascent
TM
 fluorometer (Thermo Labsystems OY, Helsinki, Finland) 
[15].  Fluorescence intensity was detected at 390 nm (excitation) and 460 nm (emission). 
Briefly, 20 ml of TCal or 20 ml of PPPLow or PPP reagent, in the presence or absence of 
0.4nM TM or 1.37nM TM respectively, were dispensed into a round bottom 96 well 
microtitre plate, where the concentration of TM used was determined as previously described 
[17]. Eighty microlitres of either TGT-RP or PPP was then added to each mixture and pre-
incubated at 37
o
C for 10 minutes. Following pre-incubation, 20 ml of FluCa was 
automatically dispensed by the analyser into each well and thrombin generation measured 
over a fixed time period. Thrombin generation curves were generated with Thrombinoscope 
Software, version 5.0.0.742 (Thrombinoscope BV). Thrombin generation was calibrated 
against the fluorescence curve obtained using a fixed amount of thrombin-alpha2-
macroglobulin complex, contained within TCal, to correct for the inner filter effect.  
 
All samples from each woman were assessed concurrently, alongside a standardised plasma 
(TGT-RP), to minimise the effect of inter-assay variability.  
 
The TG parameters measured were; endogenous thrombin potential (ETP) (nM.min, the area 
under the curve), Peak thrombin concentration (nM), lag time (min, time to first thrombin 
production), time to reach peak height (ttPeak) (min), Velocity Index (VI) (nmol/min, slope 
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between lag time and ttPeak) and start tail (min, time at which thrombin generation ceases).  
 
Statistical Analysis 
Thrombin generation test results were collected from individual experiments for statistical 
analysis. The mean, standard deviation and confidence interval were calculated for all TG 
parameters under 4 different assay conditions. One-Way ANOVA comparison (Dunnett’s test 
and Tukey’s test) was performed using GraphPad Prism Version 6.07 where statistical 
significance was given a P-value of < 0.05. 
 
 
 
Results 
196 women were recruited, resulting in 36 successful first attempt pregnancies, of which 22 
women gave birth at term with no complications occurring during the antenatal period. 
Demographic data for these 22 women is shown in Table 1, including the reason for IVF.  
 
Effect of Pregnancy on Thrombin Generation 
Thrombin generation was measured in 19 separate experiments, where all samples were 
tested in parallel with TGT-RP, under the 4 different assay conditions. To limit the effect of 
inter-assay variability, all samples from each individual woman were assessed concurrently. 
Intra-assay coefficient of variation (CV) for TGT-RP was less than 5% for all TG parameters 
and inter-assay CV ranged between 4% - 19% (data not shown).  
 
On analysis of the mean data, there was a significant increase from baseline (average of 
Study Days 0 & 3) at Study Day 29 (the 6
th
 gestational week) for peak thrombin, Endogenous 
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Thrombin Potential (ETP) and Velocity Index (VI) at all assay conditions, with the exception 
of VI at 1pM & 1pM+TM. This increase was sustained into the 8
th
 gestational week (Study 
Day 45). Table 2 summarises all mean data generated for ETP, peak and VI. No significant 
difference was observed for ttPeak, lag time or start tail (data not shown). The women’s data 
normalised to results from the standard plasma (TGT-RP) produced identical/very similar 
statistically significant outcomes (data not shown). 
 
Figure 2 illustrates an example Thrombogram of mean data from 17 subjects tested at 1pM 
TF + 1.37nM TM (data from 5 subjects excluded from the mean graph due to readings being 
taken at slightly different times on the Fluoroskan Ascent
TM
 flurometer) 
 
To minimise the effect of inter-individual variability, the mean change in thrombin 
generation over time was determined i.e. change between the pre-pregnant and pregnant state 
per individual. There was a significant change from baseline (pre-pregnancy) to Study Day 
18 (the 5
th
 gestational week) for peak thrombin, ETP and VI under 1pM TF, 1pM TF + TM 
and 5pM TF assay conditions. This increase persisted into the 6
th
 and 8
th
 gestational week 
(Study Days 29 & 45 respectively). Figure 3 illustrates data for mean percentage change 
from baseline under 1pM TF+ TM assay condition and Table 3 summarises data for all 
conditions. No significant percentage change was observed for ttPeak, lag time or start tail 
(data not shown). 
 
 
To determine whether thrombin generation continued to increase significantly as pregnancy 
progresses, statistical analyses were also carried out comparing thrombin generation data 
between Study Days 18, 29 and 45. A significant difference in mean ETP was observed 
between Study Day 18 and Study Day 29, but only under 5pM TF+TM conditions (P= 
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0.0390). A significant percentage change in ETP was observed between Study Day 18 and 29 
only using 5pM TF (P= 0.0397). Comparisons between Study Day 18 and Day 45 highlighted 
a significant increase in mean ETP and a significant percentage change in ETP across all four 
assay conditions (with the exception of mean ETP at 5pM TF). A significant increase in mean 
peak and VI and a significant percentage change in peak and VI at 5pM TF and 5pM TF + 
TM was also seen (Table 4). No significant difference was observed between Day 29 and 
Day 45 (data not shown) 
 
 
Discussion 
Our data demonstrates that thrombin generation increases in women at a very early stage of 
pregnancy, at approximately five weeks of gestation, and that this increase persists to eight 
weeks of gestation. This change is detectable using four of the more commonly used 
thrombin generation assay conditions, 1pM and 5pM TF +/- TM, the lower concentration of 
tissue factor highlighting the intrinsic pathway, the higher concentration, the extrinsic 
pathway. The addition of thrombomodulin enables evaluation of the positive feedback effect 
of thrombin on the Protein C/Protein S pathway.  
 
Ours is the first study to demonstrate the very early stage of pregnancy at which thrombin 
generation patterns begin to change. Previous studies have captured data almost exclusively 
during the late stage of the first or the early stage of the second trimester [7, 9-14]. 
Furthermore, ours is the first to capture such data in a longitudinal setting and obtain 
pregnancy outcome data.  
 
The majority of previous studies have not been longitudinal and/or do not capture pre-
pregnancy samples from women who are subsequently followed up during pregnancy [7, 9, 
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11-14]. Frequently the demonstration that pregnancy is associated with an increase in 
thrombin generation has been derived from control pooled plasma either from men, non-
pregnant women or a postpartum sample from the previously pregnant women [9, 11-14]. 
The use of control pooled plasma or postpartum samples to demonstrate changes in thrombin 
generation during pregnancy is not a valid or reliable comparison due to significant inter-
individual variability in thrombin generation. Finally, in many of these studies, thrombin 
generation assay conditions were not standardised, and/or did not include a standardised 
control plasma, which will also affect the validity of the results given the known intra and 
inter assay variation that can occur when assessing thrombin generation [18, 19].  
 
This is the first study to accurately compare pre-pregnancy and pregnancy results by 
assessing percentage change from baseline, thereby taking account of the important issue of 
inter-individual variability in thrombin generation. The data shown in Table 2 indicates the 
wide range of thrombin generation results obtained pre-pregnancy, highlighting that normal 
healthy individuals generate different levels of thrombin. When subsequent comparisons are 
made at later time points during pregnancy, by comparing the difference of two means, 
although an overall mean increase in values is seen, it is possible not all women have a 
significant change in their values between the pre-pregnant and pregnant state. By assessing 
the mean percentage change from baseline this is taken into account. We would therefore 
advocate the use of change from baseline measurements when undertaking longitudinal 
comparisons of thrombin generation data in the future. 
 
The parameters of thrombin generation which demonstrated a significant change were peak, 
ETP and VI. Lag time, ttPeak and Start Tail were not significantly affected. This may suggest 
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that the total amount of thrombin generated rather than the time at which thrombin is 
generated is more significant in the underlying hypercoagulable state of pregnancy. 
 
The prothrombotic state of pregnancy has previously been demonstrated using other 
laboratory markers [20-22]. Protein S and VIII are known to decrease and increase 
respectively in response to pregnancy although it is unknown exactly at what stage of 
pregnancy these changes occur.  If these factors do alter at a similar gestation as thrombin 
generation, this would provide evidence that these changes are contributing to the 
prothrombotic state. By using lower levels of tissue factor i.e. 1pM as opposed to 5pM, and 
thrombomodulin, in some of the assay conditions, we hope to have captured the effect these 
two proteins have on thrombin generation by highlighting the effect of the intrinsic pathway 
and the activated protein C pathway, respectively. High levels of tissue factor and the absence 
of thrombomodulin however, still enabled a change in thrombin generation to be detected 
suggesting that changes in protein S and VIII are not the only variations in coagulation 
parameters that result in the prothrombotic state of pregnancy. Further work is required to 
assess how early other parameters involved in the coagulation cascade change in pregnancy. 
 
Some previous longitudinal studies have been performed where thrombin generation has been 
measured on more than one occasion in the same women during the pregnancy. These studies 
have not concurred as to whether thrombin generation increases significantly as pregnancy 
progresses which may in part be due to a lack of standardization in experimental design [7, 9-
14]. Our study also suggests that thrombin generation may continue to increase as pregnancy 
progresses. This appears to be best reflected when thrombin generation is assessed under 
5pM assay conditions; ETP, peak and VI increased significantly between Day 18 and Day 45 
using 5pM +TM but such significant changes were only demonstrable for ETP under lower 
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tissue factor conditions (Table 4). This is perhaps surprising given that both concentrations of 
tissue factor could detect thrombin generation changes between the pre-pregnant and 
pregnant state. On review of our results we hypothesise that changes detected in thrombin 
generation between different time points during pregnancy and under some assay conditions 
may be affected by patient numbers and differences in confidence intervals. One further 
limitation of our study was samples were not taken beyond the early 1
st
 trimester to 
characterise to thrombin generation patterns as pregnancy progress. Further work is still 
required in this area. 
 
Our results suggest that hypercoagulability associated with pregnancy begins as early as four 
weeks of gestation, which is around the time of a first positive pregnancy test. We do not 
suggest from our results that thrombin generation can predict which women are at 
increased risk of venous thrombosis; simply that, those women deemed to be at high 
thrombotic risk, based on currently available clinical guidelines, will develop that higher 
risk very early in pregnancy. This is an important finding as it has previously been 
acceptable practice for those women deemed at high risk of venous thrombosis in association 
with pregnancy to start prophylaxis with low molecular weight heparin (LMWH) after the 
confirmation of a pregnancy on ultrasound, around 8-12 weeks of gestation. This study 
suggests that waiting to confirm a pregnancy on scan may be later than is safe to commence 
LMWH. Therefore we suggest that, as a result of this work, women deemed to be at high risk 
of thrombosis during pregnancy should commence thromboprophylaxis as soon as pregnancy 
is verified by a positive urinary pregnancy test. We believe that the chance of either a false 
positive pregnancy result or side effects from LMWH are outweighed by the benefits gained 
from receiving LMWH as early as possible and preventing a first trimester venous 
thrombosis. Venous thrombosis remains the third most common cause of maternal death with 
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25% of deaths occurring in the first trimester [23]. Furthermore there is significant morbidity 
associated with venous thrombosis in pregnancy, in particular post thrombotic syndrome, 
which is often more severe in pregnant women than their non pregnant counterparts due to 
the more proximal location of thromboses which occur in the pregnant state. The early 
introduction of LMWH may have the potential to reduce this rate of significant morbidity and 
even mortality. 
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Characteristics Mean (95% C.I.) or n (%) 
Age (years) 34.6 (32.4, 36.8) 
Current smoker n (%) 2 (9%) 
SIMD quintile 
1- Most affluent, 5- most deprived) 
1 
2 
3 
4 
5 
 
 
3 (14%) 
5 (23%) 
4 (18%) 
5 (23%) 
5 (23%) 
SBP (mmHg) 118 (112, 124) 
DBP(mmHg) 65 (62, 69) 
Height (m) 1.7 (1.6, 1.7) 
Weight (kg) 73.0 (67.3, 78.6) 
BMI (kg/m
2
) 27.0 (24.8, 29.1) 
Waist (cm) 90.1 (85.2, 95.0) 
Menstrual period length (days) 4.4 (3.7, 5.1) 
Cycle length (days) 29.0 (28.2, 29.9) 
Number of previous pregnancies ≥24 weeks 
0 
1 
2 
 
22 (100%) 
0 (0%) 
0 (0%) 
Number of previous pregnancies <24 weeks 
0 
1 
2 
3 
 
14 (64%) 
4 (18%) 
3 (14%) 
1 (5%) 
Number of embryos transferred 
1 
2 
3 
 
5 (23%) 
16 (73%) 
1 (5%) 
Reason for infertility n (%) 
Male 
Female 
 
9 (40.9%) 
13 (59.1%) 
Treatment 
IVF 
ICSI 
 
13 (36%) 
23 (64%) 
Table
Table 1. Demographic data for women undergoing IVF, which resulted in a normal 
pregnancy outcome (n=22)  
 Table 2: Mean thrombin generation raw data for pre-pregnancy and early pregnancy  
 
 
 
 
Table 2. Mean raw data for ETP, peak and velocity Index; mean (95% confidence intervals). (a) represents p<0.05; (b) represents p<0.01; (c) 
represents p<0.001; (d) represents p<0.0001. P represents the comparison between the mean at baseline (average of Day 0 and Day 3) and the 
mean at time points during early pregnancy e.g. Study Day 29, Study Day 45. P values are based on ANOVA for continuous variables. n= 
Day 0 (LH  surge) 
(n=21)
Day 3 (FET) (n=22) Day 7 (n=13) Day 10 (n=12) Day 18  (n=22) Day 29 (n=16) Day 45 (n=19)
1pM TF 1278 (1183, 1373) 1201 (1103, 1300) 1258 (1090, 1426) 1283 (1130, 1435) 1397 (1289, 1506) (b) 1514 (1362, 1666)
(d) 
1610 (1483, 1738)
1pM TF +TM 894 (768, 1019) 760 (621, 898) 923 (717, 1130) 1007 (839, 1175) 1019 (877, 1161) (c) 1186 (1019, 1352)
(d) 
1278 (1144, 1413)
5pM TF 1436 (1333, 1539) 1435 (1333, 1537) 1451 (1311, 1591) 1426 (1290, 1562) 1550 (1437, 1662) (a) 1656 (1497, 1815)
(c) 
1742 (1592, 1892)
5pM TF + TM 799 (669, 929) 759 (649, 868) 892 (703, 1081) 929 (771, 1086) 858 (708, 1008) (c) 1099 (954, 1245)
(d) 
1197 (1075, 1318)
1pM TF 194 (165, 223) 162 (135, 189) 192 (148, 236) 201 (168, 235) 213 (187, 239) (a) 228 (196, 261)
(c) 
246 (220, 273)
1pM TF +TM 167 (137, 197) 136 (107, 165) 172 (127, 217) 186 (151, 222) 190 (161, 218) (b) 211 (177, 246)
(c) 
230 (201, 260)
5pM TF 250 (223, 277) 247 (224, 270) 263 (223, 303) 264 (236, 292) 278 (253, 304) (b) 308 (274, 343)
(d) 
331 (304, 359)
5pM TF + TM 170 (141, 199) 164 (141, 188) 196 (155, 237) 200 (169, 231) 191 (158, 224) (c) 239 (207, 270)
(d) 
266 (237, 295)
1pM TF 53 (40, 66) 41 (30, 52) 53 (36, 70) 57 (41, 73) 61 (49, 73) 62 (48, 75) (b)72 (58, 86)
1pM TF +TM 52 (39, 64) 41 (30, 52) 53 (37, 70) 59 (43, 76) 61 (49, 72) 66 (51, 80) (b)72 (59, 86)
5pM TF 84 (69, 99) 83 (70, 96) 95 (73, 118) 97 (81, 113) 100 (84, 115)
(b)
119 (99, 139)
(d)
131 (114, 149)
5pM TF + TM 69 (55, 82) 65 (55, 75) 84 (64, 104) 83 (68, 99) 79 (64, 94)
(c)
100 (85, 115)
(d)
119 (103, 136)
1pM TF 8.6 (8.0, 9.3) 9.1 (8.4, 9.8) 8.7 (7.8, 9.5) 8.4 (7.6, 9.2) 8.7 (8.1, 9.3) 8.4 (7.7, 9.0) 8.4 (7.7, 9.1)
7.8 (7.3, 8.3)
5.2 (4.9, 5.5)
4.8 (4.6, 5.0)
4.6 (4.2, 5.0)
4.5 (4.1, 4.9)
2.6 (2.5, 2.8)
2.5 (2.4, 2.7)
25.5 (24.3, 26.7)
23.2 (22.5, 23.9)
21.8 (20.9, 22.8)
19.6 (19.0, 20.3)
ETP 
(nM.min)
Peak 
thrombin 
(nM)
Velocity 
Index
Table
number of samples available for analysis at that time point. ETP: endogenous thrombin potential; LH: lutenizing hormone; FET: frozen embryo 
transfer 
Table 3: Mean percentage change in thrombin generation between pre-pregnancy and 
early pregnancy 
 
 
 
Table 3: Mean percentage change in thrombin generation between pre-pregnancy and early 
pregnancy. Pre-pregnancy values are an average of Study Day 0 and Study Day 3. This 
average is recalculated as zero. Each box represents the mean percentage change from 
baseline with 95% confidence intervals in brackets. (a) represents p<0.05; (b) represents 
p<0.01; (c) represents p<0.001; (d) represents p<0.0001. P represents the mean percentage 
change from baseline at given time points during early pregnancy e.g. Study Day 29, Study 
Day 45. P values are based on ANOVA for continuous variables. n= number of samples 
available for analysis at that time point. ETP: endogenous thrombin potential; TF: tissue 
factor; TM: thrombomodulin 
 
 
 
 
 
Day 7 (n=13) Day 10 (n=12) Day 18 (n=22) Day 29 (n=16) Day 45 (n=19)
1pM TF 1 (-6, 8) 4 (-2, 9) (d)13 (9, 18)
(d)
23 (18, 27)
(d)
31 (23,39)
1pM TF +TM 11 (-6, 28) 20 (9, 31) (b)30 (15, 46)
(d)
49 (29, 68)
(d)
69 (45, 93)
5pM TF 0 (-4, 4) 0 (-3, 3) (c)8 (5, 11)
(d)
15 (12, 18)
(d)
22 (17, 28)
5pM TF + TM 3 (-7, 13) 8 (2, 14) 12 (0, 25) (c)46 (13, 80)
(d)
68 (36, 101)
1pM TF 10 (-8, 28) 17 (6, 27) (c)28 (14, 43)
(c)
34 (17, 50)
(d)
47 (28, 66)
1pM TF +TM 13 (-9, 35) 23 (12, 34) (c)39 (21, 58)
(c)
48 (24, 72)
(d)
70 (41, 99)
5pM TF 2 (-7, 11) 5 (2, 7) (b)13 (7, 20)
(d)
24 (15, 32)
(d)
39 (25, 52)
5pM TF + TM 5 (-8, 19) 11 (5, 16) 16 (4, 29) (d)49 (15, 82)
(d)
75 (42, 108)
1pM TF 22 (-8, 52) 30 (15, 46) (b)49 (18, 79)
(b)
48 (19, 78)
(d)
74 (39, 109)
1pM TF +TM 18 (-8, 45) 29 (16, 42) (b)49 (21, 77)
(b)
57 (22, 92)
(d)
84 (42, 126)
5pM TF 6 (-9, 21) 13 (6, 19)
(a)
23 (12, 34)
(d)
44 (21, 67)
(d)
71 (42, 101)
5pM TF + TM 13 (-8, 33) 17 (8, 26) 20 (7, 34)
(d)
58 (21, 96)
(d)
100 (60, 141)
-6.7 (-12.2, 1.2)
-4.3 (-8.4, -0.3)
-8.9 (-12.9, -4.9)
-4.9 (-7.5, -2.3)
-2.2 (-6.9, 2.4)
-4.5 (-9.1, 0.0)
0.6 (-2.9, 4.1)
2.5 (-2.6, 7.6)
-0.9 (-5.6, 3.8)
3.6 (1.3 5.9)
-0.2 (-3.5, 3.1)
1.6 (-0.8, 3.9)
ETP 
(nM.min)
Peak 
thrombin 
(nM)
Velocity 
Index
Table
Table 4: Changes in thrombin generation during early pregnancy 
Day 18 vs. Day 29 
     
 
ETP Peak Velocity Index 
 
Mean 
data 
% 
change 
Mean 
data 
% 
change 
Mean 
data 
% 
change 
1pM 0.3786 0.841 0.72 0.8917 0.9977 0.9997 
1pM + TM 0.2294 0.3683 0.5587 0.8486 0.8478 0.9364 
5pM 0.4981 0.0397 0.2855 0.2629 0.2555 0.3304 
5pM + TM 0.039 0.1356 0.0748 0.1661 0.1326 0.1636 
       Day 18 vs. Day 45 
     
 
ETP Peak Velocity Index 
 
Mean 
data 
% 
change 
Mean 
data 
% 
change 
Mean 
data 
% 
change 
1pM 0.0319 0.0002 0.1715 0.2122 0.4053 0.4553 
1pM + TM 0.0238 0.0112 0.1119 0.1302 0.353 0.2825 
5pM 0.0906 < 0.0001 0.0165 0.0006 0.0188 0.0028 
5pM + TM 0.0017 0.0042 0.0018 0.0031 0.0007 0.0005 
 
Table 4: Changes in thrombin generation during early pregnancy. Values in each box are the 
p values obtained when analysing either differences in the means or mean percentage 
changes, between two time points in pregnancy using ANOVA. P values <0.05 are 
highlighted in bold. ETP: endogenous thrombin potential; TF: tissue factor; TM: 
thrombomodulin 
 
 
Table
LH Surge
FET
Study Day
Gestation Day 14
(Wk 2)
Day 17
(Wk 2.4)
Day 21
(Wk 3)
Day 24
(Wk 3.4)
Pregnancy Test
hCG
Day 32
(Wk 4.6)
Day 43
(Wk 6.1)
Ultrasound Scan
+ve fetal heartbeat
Day 59
(Wk 8.4)
LMP
Day 0
(Week 0)
Day -14 Day 0 Day 3 Day 7 Day 10 Day 18 Day 29 Day 45
Figure 1: Sample Time Points and Equivalent Gestational Period
LH: lutenizing hormone; FET: frozen embryo transfer; hCG: human chorionic gonadotrophin
Figure
Figure 2: Thrombogram at 1pM TF +TM 
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Figure
 Figure 2. Mean thrombin generation from 17 subjects measured pre-pregnancy (baseline) and at 
Study Day 18, 29 and 45 (equivalent of Gestation Day 32, 43 and 59) 
 
 
 Figure 3. Mean percentage change from baseline in early pregnancy in thrombin generation at 1pM TF + TM 
 
 
 
Figure 3 Mean data +/- 95% C.I. for percentage change from baseline under 1pM TF+ TM. Baseline is the mean of Study Day 0 and Study Day 3. Change from 
baseline is the change in a thrombin generation parameter between baseline and a given time point in early pregnancy e.g. Day 18 compared to baseline. 
** represents p<0.01; ***represents p<0.001; **** represents p<0.0001. TF: tissue factor; TM: thrombomodulin; ETP: endogenous thrombin potential 
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